title: Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
abstract: The last article in this 5-part series provides a final overview of consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. Optimal management of rosacea requires careful assessment of the patient's clinical features with integration of therapies that adequately treat the presenting signs and symptoms. The treatment consensus recommendations from the AARS are based on 2 major common clinical presentations of rosacea: (1) centrofacial erythema with papulopustular lesions, and (2) centrofacial erythema without papulopustular lesions. The recommendations provided here serve to guide clinicians in their clinical practice.
authors.affiliation: jqdelrosso@yahoo.com.
authors.forename: James Q
authors.initials: JQ
authors.lastname: Del Rosso
authors.forename: Diane
authors.initials: D
authors.lastname: Thiboutot
authors.forename: Richard
authors.initials: R
authors.lastname: Gallo
authors.forename: Guy
authors.initials: G
authors.lastname: Webster
authors.forename: Emil
authors.initials: E
authors.lastname: Tanghetti
authors.forename: Lawrence F
authors.initials: LF
authors.lastname: Eichenfield
authors.forename: Linda
authors.initials: L
authors.lastname: Stein-Gold
authors.forename: Diane
authors.initials: D
authors.lastname: Berson
authors.forename: Andrea
authors.initials: A
authors.lastname: Zaenglein
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D058647:Adrenergic alpha-2 Receptor Agonists / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000068438:Brimonidine Tartrate; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003998:Dicarboxylic Acids / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D004890:Erythema / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D012393:Rosacea / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index; D012955:Societies, Medical
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D000890:Anti-Infective Agents; D003879:Dermatologic Agents; D003998:Dicarboxylic Acids; D011810:Quinoxalines; D008795:Metronidazole; D000068438:Brimonidine Tartrate; C010038:azelaic acid; D004318:Doxycycline